Literature DB >> 3600950

Divergent changes in D-1 and D-2 dopamine binding sites in human brain during aging.

D G Morgan, J O Marcusson, P Nyberg, P Wester, B Winblad, M N Gordon, C E Finch.   

Abstract

The density of D-1 and D-2 dopamine receptors in human caudate nucleus and putamen, obtained postmortem, were studied throughout the adult lifespan using [3H]fluphenazine as the dopamine receptor ligand. The D-1 subtype increased progressively with age in both regions, while the D-2 subtype declined in caudate nucleus. The ratio of D-1/D-2 Bmax in both regions increased from approximately 1 at age 20 to 2 by age 75. The dopamine content in putamen declined with age and was inversely correlated with D-1 receptor density. We suggest that D-1 receptor density is up-regulated by loss of dopamine during aging. The D-2 receptor density in caudate nucleus was positively correlated with choline acetyltransferase activity, suggesting that loss of intrastriatal neurons with age may contribute to the decrease in D-2 sites. These divergent changes in dopamine receptor subtypes with age result in an altered complement of dopamine receptors in older humans and may provide a basis for selective pharmacotherapy in disorders of the basal ganglia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3600950     DOI: 10.1016/0197-4580(87)90002-9

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  14 in total

1.  Analysis of genetic variations in the dopamine D1 receptor (DRD1) gene and antipsychotics-induced tardive dyskinesia in schizophrenia.

Authors:  I-Ching Lai; Geng-Han Mo; Mao-Liang Chen; Ying-Chieh Wang; Jen-Yeu Chen; Ding-Lieh Liao; Ya-Mei Bai; Chao-Cheng Lin; Tzu-Ting Chen; Ying-Jay Liou
Journal:  Eur J Clin Pharmacol       Date:  2010-12-22       Impact factor: 2.953

2.  Age-related changes in human D1 dopamine receptors measured by positron emission tomography.

Authors:  T Suhara; H Fukuda; O Inoue; T Itoh; K Suzuki; T Yamasaki; Y Tateno
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels.

Authors:  J C Baron; J L Martinot; H Cambon; J P Boulenger; M F Poirier; V Caillard; J Blin; J D Huret; C Loc'h; B Maziere
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Striatal dopamine D2 receptors in tardive dyskinesia: PET study.

Authors:  J Blin; J C Baron; H Cambon; A M Bonnet; B Dubois; C Loc'h; B Mazière; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-11       Impact factor: 10.154

Review 5.  Primate aging in the mammalian scheme: the puzzle of extreme variation in brain aging.

Authors:  Caleb E Finch; Steven N Austad
Journal:  Age (Dordr)       Date:  2012-01-05

Review 6.  Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky.

Authors:  David S Goldstein; Irwin J Kopin
Journal:  Cell Mol Neurobiol       Date:  2017-05-09       Impact factor: 5.046

7.  Age-associated improvements in cross-modal prepulse inhibition in mice.

Authors:  Jared W Young; Chelsea K Wallace; Mark A Geyer; Victoria B Risbrough
Journal:  Behav Neurosci       Date:  2010-02       Impact factor: 1.912

8.  Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists.

Authors:  H Lublin; J Gerlach; F Mørkeberg
Journal:  Psychopharmacology (Berl)       Date:  1994-04       Impact factor: 4.530

Review 9.  Monoamine neurons in aging and Alzheimer's disease.

Authors:  A M Palmer; S T DeKosky
Journal:  J Neural Transm Gen Sect       Date:  1993

10.  Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans.

Authors:  H Toyama; M Ichise; J R Ballinger; L Fornazzari; J C Kirsh
Journal:  Ann Nucl Med       Date:  1993-02       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.